Plain-English translation of NCT06914037 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase 1) testing a new treatment called , which is a type of immunotherapy using modified immune cells designed to attack cancer cells. The trial will enroll about 24 patients with advanced T-cell or B-cell blood cancers that have stopped responding to standard treatments. Researchers will carefully monitor your health and safety while studying how the medication works in your body.
Many people with advanced blood cancers run out of effective treatment options after their cancer becomes resistant to standard therapies. This medication targets a specific marker (called CD70) found on cancer cells, offering a potentially new approach for patients who have exhausted other options.
You likely qualify if…
You likely don't qualify if…
You would receive infusions at the hospital or clinic as part of the study. The trial starts with a dose-escalation phase where the research team carefully increases doses in small groups of patients to find the safest and most effective level. Throughout your participation, you'll have blood tests, imaging scans, and visits with the research team to monitor how well the treatment is working and how you're tolerating it. The exact schedule and duration depend on how your body responds to the medication.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Enrollment target
~24 participants
Started
March 2025
Primary completion
March 2028
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huilai Zhang
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.